重組蛋白

重組蛋白質(zhì)是分析生物相互作用的有用工具。在研究實驗室中使用了大量的重組蛋白質(zhì),包括商業(yè)蛋白質(zhì)和在特定研究項目中生成的蛋白質(zhì)。它們在許多應(yīng)用中發(fā)揮著關(guān)鍵作用。
如果您正在尋找具有優(yōu)良質(zhì)量(驗證的生物活性,較低的內(nèi)毒素水平和高純度)的重組蛋白質(zhì)來支持您的研究,您來對地方了。
經(jīng)過18年的發(fā)展,華美生物已經(jīng)建立了從原核到真核的五大系統(tǒng),用于表達重組蛋白質(zhì)。我們擁有一系列蛋白質(zhì)表達和純化技術(shù),包括基于桿狀病毒外膜蛋白(OMP)的蛋白質(zhì)表達技術(shù),以及膜蛋白表達技術(shù)等。
產(chǎn)品特點
- 超過13,000種重組蛋白覆蓋大多數(shù)基因/靶點;
- 5種表達系統(tǒng),包括大腸桿菌(E.coli)、酵母、桿狀病毒感染的昆蟲細胞、哺乳動物細胞和體外大腸桿菌。而體外大腸桿菌表達系統(tǒng)是華美生物的獨特表達系統(tǒng)。與傳統(tǒng)蛋白表達系統(tǒng)相比,體外大腸桿菌省略了許多過程,如質(zhì)粒轉(zhuǎn)化、細胞培養(yǎng)、收集、破碎和離心等,大大提高了工作效率。
- 多種標簽,包括His、GST、Flag、MBP等。
- 廣泛應(yīng)用,包括抗原、細胞分析、結(jié)合分析/蛋白質(zhì)相互作用、細胞培養(yǎng)-無血清培養(yǎng)基、藥物相關(guān)研究、體外酶活性、ELISA標準及其原料、體內(nèi)研究、質(zhì)譜標準、蛋白芯片、SDS-PAGE控制、蛋白質(zhì)結(jié)構(gòu)分析(晶體/電子顯微鏡)。
- 多種物種,包括人類、小鼠、大鼠、兔子、豚鼠、雞、猴子、豬等。
- 無動物副產(chǎn)品的動物源性重組蛋白質(zhì)。華美生物已開發(fā)出無動物副產(chǎn)品接觸的重組蛋白質(zhì)產(chǎn)品線。
重組蛋白目錄
以下是所有重組蛋白的目錄。您可以在目錄中找到適合您研究的蛋白質(zhì),或在本網(wǎng)站頭部的搜索框中搜索它們。
如果您找不到您需要的抗體,請查看華美生物蛋白質(zhì)定制服務(wù)。
通過選擇目標名稱的首字母瀏覽產(chǎn)品。
產(chǎn)品名稱 | 貨號 | 規(guī)格 |
---|---|---|
Recombinant Haemophilus influenzae Uncharacterized protein HI_0388 (HI_0388) | CSB-YP332037HTA CSB-EP332037HTA CSB-BP332037HTA CSB-MP332037HTA CSB-EP332037HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0391 (HI_0391) | CSB-YP332038HTA CSB-EP332038HTA CSB-BP332038HTA CSB-MP332038HTA CSB-EP332038HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae UPF0125 protein HI_0395 (HI_0395) | CSB-YP332039HTA CSB-EP332039HTA CSB-BP332039HTA CSB-MP332039HTA CSB-EP332039HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0421 (HI_0421) | CSB-YP332040HTA CSB-EP332040HTA CSB-BP332040HTA CSB-MP332040HTA CSB-EP332040HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0451 (HI_0451) | CSB-YP332041HTA CSB-EP332041HTA CSB-BP332041HTA CSB-MP332041HTA CSB-EP332041HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0453 (HI_0453), partial | CSB-YP332042HTA1 CSB-EP332042HTA1 CSB-BP332042HTA1 CSB-MP332042HTA1 CSB-EP332042HTA1-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0476 (HI_0476) | CSB-YP332043HTA CSB-EP332043HTA CSB-BP332043HTA CSB-MP332043HTA CSB-EP332043HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0488 (HI_0488) | CSB-YP332044HTA CSB-EP332044HTA CSB-BP332044HTA CSB-MP332044HTA CSB-EP332044HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae S-ribosylhomocysteine lyase (luxS) | CSB-YP332045HTA CSB-EP332045HTA CSB-BP332045HTA CSB-MP332045HTA CSB-EP332045HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae UPF0114 protein HI_0507 (HI_0507), partial | CSB-YP332046HTA1 CSB-EP332046HTA1 CSB-BP332046HTA1 CSB-MP332046HTA1 CSB-EP332046HTA1-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Probable ribonuclease HI_0526 (HI_0526) | CSB-YP332047HTA CSB-EP332047HTA CSB-BP332047HTA CSB-MP332047HTA CSB-EP332047HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0557 (HI_0557) | CSB-YP332048HTA CSB-EP332048HTA CSB-BP332048HTA CSB-MP332048HTA CSB-EP332048HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0577 (HI_0577) | CSB-YP332049HTA CSB-EP332049HTA CSB-BP332049HTA CSB-MP332049HTA CSB-EP332049HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Putative uncharacterized transporter HI_0586 (HI_0586), partial | CSB-YP332050HTA1 CSB-EP332050HTA1 CSB-BP332050HTA1 CSB-MP332050HTA1 CSB-EP332050HTA1-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0589 (HI_0589), partial | CSB-YP332051HTA1 CSB-EP332051HTA1 CSB-BP332051HTA1 CSB-MP332051HTA1 CSB-EP332051HTA1-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0594 (HI_0594), partial | CSB-YP332052HTA CSB-EP332052HTA CSB-BP332052HTA CSB-MP332052HTA CSB-EP332052HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0633 (HI_0633), partial | CSB-YP332053HTA1 CSB-EP332053HTA1 CSB-BP332053HTA1 CSB-MP332053HTA1 CSB-EP332053HTA1-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized glycosyltransferase HI_0653 (HI_0653) | CSB-YP332054HTA CSB-EP332054HTA CSB-BP332054HTA CSB-MP332054HTA CSB-EP332054HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Uncharacterized protein HI_0660 (HI_0660) | CSB-YP332055HTA CSB-EP332055HTA CSB-BP332055HTA CSB-MP332055HTA CSB-EP332055HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
Recombinant Haemophilus influenzae Cell division protein FtsB (ftsB), partial | CSB-YP332056HTA CSB-EP332056HTA CSB-BP332056HTA CSB-MP332056HTA CSB-EP332056HTA-B |
20μg/100μg/1mg(1mg*1 or 500ug*2) |
有用資源
什么是重組蛋白?
重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達載體的選擇、表達蛋白的長度(全長或部分)、是否帶標簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。
第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。
第二條:如何選擇合適的表達載體?
表達載體是一種DNA分子,它攜帶特定的基因進入宿主細胞,并利用細胞的蛋白質(zhì)合成機制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達載體可使外源基因在宿主細胞中高效表達,經(jīng)過多年的發(fā)展,表達載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達載體。
根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達服務(wù),您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點擊橙色按鈕為我們在線留言。
引用資料
Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023
Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023
Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023
Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023
Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022